GlassScriptPhysician profile
Humayun Jamidar
NPI 1417921701
$10,487.78
in general payments reported to CMS, 2019-2025
42 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,765 · 2020: $1,010 · 2021: $1,943 · 2022: $1,569 · 2023: $1,917 · 2024: $1,456 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,115 · Education: $64.99 · Debt Forgiveness: $21.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,114.99 |
| Education | $64.99 |
| Debt Forgiveness | $21.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,125.26 | 2019-2023 | Xarelto |
| Amgen INC. | $998.08 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $839.20 | 2019-2025 | Watchman Access System, Watchman Flx, Versacross Access Solution |
| Abiomed | $763.60 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $732.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $507.46 | 2019-2025 | Farxiga, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $486.03 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.61 | 2019-2025 | Jardiance |
| Cvrx, INC. | $419.55 | 2019-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $397.54 | 2019-2023 | |
| Pfizer INC. | $397.19 | 2019-2025 | |
| Cardiovascular Systems INC. | $389.95 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $311.27 | 2019-2023 | Onpattro |
| Esperion Therapeutics, INC. | $290.57 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $249.18 | 2021-2024 | Ozempic, Wegovy |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $222.69 | 2019-2022 | |
| Abbott Laboratories | $219.67 | 2019-2025 | Amplatzer Amulet, Diamondback Coronary, Merlin@Home |
| Merck Sharp & Dohme LLC | $213.73 | 2021-2025 | Verquvo |
| Shockwave Medical, INC | $188.67 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $173.56 | 2022-2025 | Micra |
| Cleerly, INC. | $146.85 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Medtronic Vascular, INC. | $142.82 | 2019-2020 | |
| Lilly USA, LLC | $118.61 | 2022-2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $79.88 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $68.39 | 2021-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $62.42 | 2022-2025 | |
| Arineta, INC | $60.10 | 2024 | Spotlight |
| Kestra Medical Technology Services, INC. | $50.66 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.54 | 2019-2023 | Lifevest |
| Philips North America LLC | $44.14 | 2020-2024 | (Ck7) Extended Holter |
| Impulse Dynamics (USA) INC. | $38.88 | 2021 | |
| Edwards Lifesciences Corporation | $34.50 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $33.84 | 2023 | Inpefa |
| Bardy Diagnostics, INC. | $24.00 | 2020-2021 | |
| Scpharmaceuticals INC. | $23.79 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $21.95 | 2019 | |
| Daiichi Sankyo INC. | $17.87 | 2023 | Injectafer |
| Irhythm Technologies, INC. | $16.70 | 2020 | |
| Csl Behring | $15.28 | 2025 | Kcentra |
| Portola Pharmaceuticals, LLC | $15.15 | 2020 | |
| Livanova USA, INC. | $14.54 | 2023 | Protekduo |
| Genzyme Corporation | $12.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humayun Jamidar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.